踏入2024年以来，创新药产业持续释放积极信号。今年本土创新药出海交易额已超200亿美元，最近医保续约和谈判也有望促进国内创新药长期放量。市场预期转好之下，生物医药板块在新一轮牛市中进入了估值修复的阶段。HSHKBIO（恒生香港上市生物科技指数）近三个月以来累计上涨近31%。在此背景下，港股迎来了“合成生物学医药第一股”——华昊中天医药-B(2563.HK)。华昊中天医药-B（以下简称“华昊中天”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.